XJPX
4880
Market cap38mUSD
Oct 09, Last price
311.00JPY
1D
1.30%
1Q
-10.37%
IPO
-60.13%
Name
CellSource Co Ltd
Chart & performance
P/E
579.09
P/S
1.66
EPS
0.54
Div yield, %
1.63%
Shrs. gr., 5y
0.78%
Rev. gr., 5y
14.87%
Revenues
3.71b
-14.78%
Net income
11m
-95.52%
CFO
333m
-43.71%
Dividend
Oct 30, 20255 JPY/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
CellSource Co., Ltd. operates within both the regenerative medicine and consumer product sectors. Among its offerings is Signalift, an anti-aging solution. The company, which was established in 2015, is headquartered in Tokyo, Japan.
Key people
Masayuki Yamakawa
Chairman of the Board, Representative Director · since 2025
President, Chief Executive Officer, Representative Director · since 2024
Kaoru Hosoda
Executive Officer, Chief Operating Officer, Chief Director of Contract Processing Business · since 2024
Hirohiko Hanaki
Executive Officer, Chief Director of Medical Affairs · since 2022
Yuta Hayashi
Executive Officer, Chief Strategy Officer, Chief Director of Business Strategy · since 2024
Tomohiro Iga
Executive Officer · since 2024
Katsuji Onishi
Executive Officer, Chief Director of Regenerative Medicine · since 2022
Executive Officer, Chief Director of Corporate · since 2023
Masato Tsumamoto
Chief Transformation Officer, Director · since 2024
Takeshi Amemiya
Director · since 2022
Independent Director · since 2021
Yoshitake Kamino
Independent Director · since 2026
Norio Murakami
Independent Director · since 2017
Independent Director · since 2023
Independent Director · since 2025
Valuation
Title JPY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2025‑10 | 2024‑10 | 2023‑10 | 2022‑10 | 2021‑10 | 2020‑10 | 2019‑10 | 2018‑10 | 2017‑10 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | |||||||||
Unusual Expense (Income) | |||||||||
NOPBT | |||||||||
NOPBT Margin | |||||||||
Operating Taxes | |||||||||
Tax Rate | |||||||||
NOPAT | |||||||||
Net income | |||||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | |||||||||
| Cash flow | |||||||||
Cash from operating activities | |||||||||
CAPEX | |||||||||
Cash from investing activities | |||||||||
Cash from financing activities | |||||||||
FCF | |||||||||
| Balance | |||||||||
Cash | |||||||||
Long term investments | |||||||||
Excess cash | |||||||||
Stockholders' equity | |||||||||
Invested Capital | |||||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | |||||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | |||||||||
EV/EBITDA | |||||||||
Interest | |||||||||
Interest/NOPBT | |||||||||